Q3 2020 Sales Performance

GSK'609: progressing to advanced trials and novel combinations Solid tumours INDUCE-1 POC Relapsed/refractory selected solid tumours Open label dose escalation and expansion study of GSK'609 monotherapy and combination with pembrolizumab n= >500 Study start Read-out 2016 NA gsk Relapsed/refractory INDUCE-2 POC HNSCC HNSCC Open label dose escalation and expansion study of GSK'609 in combination with tremelimumab N=114 Dec'18 2021 55k Ph2/3 INDUCE-3 1L PD-1 positive recurrent or recurrent or metastatic gated metastatic HNSCC Randomised, double blind, adaptive study of GSK'609 in combination with pembrolizumab vs placebo. N=600 Dec 19 2023 patients* 1L PD-L1 total Randomised, double blind, adaptive Ph2/3 population recurrent INDUCE-4 gated or metastatic HNSCC study of GSK'609 in combination with pembrolizumab and CT vs placebo (+pembro+CT) N=640 Aug'20 2024 NSCLC relapsed/refractory advanced ENTRÉE Relapsed/refractory platform NSCLC Open label platform study of novel regimens of GSK'609 mono and combo versus SoC n=105 Jan'19 2021 130k patients* * Drug-treated patients. Source: Kantar Patient Matrix for US, EU5 and Japan in 2019, September 2019 POC = proof of concept; HNSCC = head and neck squamous cell carcinoma; SoC = standard of care; NSCLC = non small cell lung cancer 57

View entire presentation